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Abstract
Background: The KDIGO Clinical Practice Guidelines for Glomerulonephritis recommended tacrolimus as an alternative
regimen for the initial therapy for Idiopathic membranous nephropathy (IMN), however, large observational studies
evaluating tacrolimus treatment in IMN remains rare.
Methods: A total of 408 consecutive IMN patients with nephrotic syndrome who were treated with tacrolimus in Jinling
Hospital were included. The effectiveness and safety of tacrolimus treatment in IMN were analyzed in this study.
Results: The cumulative partial or complete remission after tacrolimus therapy were 50%, 63% and 67% at 6, 12 and
24 months, respectively, and the cumulative complete remission rates were 4%, 13% and 23%, respectively. Multivariate
logistic analysis showed that higher tacrolimus exposure during induction treatment, female gender, higher eGFR and
no history of previous immunosuppressive therapy were independently associated with higher probability of remission. A
relapse occurred in 101 of the 271 (37.3%) patients with partial or complete remission, and 18 of the 95 (18.9%) patients
with complete remission. Tapering duration of tacrolimus and complete remission versus partial remission status were
independent factors associated with risk of relapse. A decline in eGFR was the most frequent adverse event during
tacrolimus treatment. During tacrolimus treatment, a ≥40% decrease in eGFR was observed in 43 (10.5%) patients.
Conclusions: Low dose tacrolimus is effective for IMN, with a total remission rate of 66% whereas with a rather high
rate of relapse. However, the safety of tacrolimus treatment needs to be further validated in large randomized clinical
trials.
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Background
Idiopathic membranous nephropathy (IMN) is the most
common cause of nephrotic syndrome in adults. Recent
data showed that the IMN is an organ specific, antibody
mediated autoimmune disease, in which the main target
antigen was M-type phospholipase A2 receptor located
on the podocyte [1].
The KDIGO guideline has recommended the combin-
ation of cyclophosphamide and steroids in cyclical fashion
as the first line treatment for IMN, which was proved to
be effective in several randomized clinical trials [2, 3]. Re-
cently, a RCT comparing chlorambucil and cyclosporine
A indicated that chlorambucil might induce a better out-
come in IMN patients with deteriorated renal function at
baseline [4]. However, the severe side effects induced by
cytotoxic regimens like cyclophosphamide or chlorambu-
cil restricted its wide application. Besides these regimens,
rituximab, a monoclonal antibody against B cell surface
antigen CD20, were reported to be able to reduce protein-
uria while stabilizing renal function [5]. Although seem-
ingly promising, large RCT study on rituximab was rare
and the drug was rather expensive.
Calcineurin inhibitors (CNIs) was recommended by
the KDIGO guideline as the only alternative regimens
for initial therapy. Various studies has demonstrated the
efficacy of CNIs (tacrolimus or cyclosporine A) in IMN
[6–15]. The most limitation of these studies were the
small number of the enrolled patients, and lack of large
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observational studies evaluating the effectiveness, safety
and chance of relapse. Here, we present real-world clinical
practice data from the largest IMN cohort till now of 408
patients with nephrotic syndrome from the Nanjing
Glomerulonephritis Registry who were treated with tacro-
limus. The aim of the study was to evaluate the effective-
ness and safety of tacrolimus in the treatment of IMN.
Methods
Patients
A total of 706 consecutive biopsy-proven IMN cases treated
with tacrolimus during follow-up in the Nanjing Glomer-
ulonephritis Registry from February 2004 to November
2013 were screened in this study. All patients were from
Chinese population. Patients who did not have NS, defined
as a proteinuria ≥3.5 g/day along with serum albumin
<30 g/L at the onset of tacrolimus treatment, were ex-
cluded. Patients who were lost to follow up after tacrolimus
treatment (follow-up <2 months for preliminary screening),
who did not follow the doctor’s orders, who exhibited coex-
isting glomerulonephritis and who were also treated with
other immunosuppressive drugs during tacrolimus treat-
ment were also excluded. All of these patients were clinic-
ally ruled out for secondary membranous nephropathy,
including anti-nuclear antibody, Hepatitis B virus infection,
blood tumor markers and abdominal ultrasound.
The pre-dose trough concentration (C0) was routinely
monitored during treatment. Tacrolimus was administered
at 0.03–0.06 mg/kg/d initially and adjusted to a pre-dose
trough concentration level (C0) of 4 to 8 ng/mL for at
least 6 months, which was then reduced gradually. Tacro-
limus was given twice per day in patients included. The ta-
crolimus blood concentration were detected routinely at
two weeks. If the target level of tacrolimus concentration
was not achieved, the dosage will be adjusted and the con-
centration will be detected at the next follow-up, deter-
mined by clinical physicians. During the maintenance
period of treatment, the concentration would only be de-
tected when necessary (judged by clinical physicians). The
reduction of tacrolimus dosage was judged by clinical phy-
sicians according to the response of treatment and pa-
tients’ tolerance. Steroid was given as 0.5 mg/kg/d as
inducing treatment for two months. After two months,
the steroid dose was reduced gradually (at a speed of
5 mg/month) to 10 mg and maintained for at least two
years. All follow-up data were updated to July, 2015. The
study was approved by Jinling Hospital Ethics Committee.
Due to the retrospective nature of the study, written in-
formed consent for participation was waived. The study
adhered to the STROBE guidelines.
Definitions
Partial remission (PR) was defined based on a urinary
protein excretion >0.3 g/d, but <3.5 g/d, and a 50% or
greater reduction from baseline value; confirmed by two
values at least 1 week apart, accompanied by an im-
provement or normalization of the serum albumin con-
centration. Complete remission (CR) was defined by a
urinary protein excretion <0.3 g/d, confirmed by two
values at least 1 week apart, accompanied by a normal
serum albumin concentration (>35 g/L). A relapse was
defined by the reappearance of proteinuria >3.5 g/24 h
after PR or CR during follow-up.
The induction period of tacrolimus treatment was de-
fined as the first 6 months of tacrolimus therapy. For
each patient, the tacrolimus exposure during inducing
period (Tacrolimus exposure) was defined as the ratio of
the area under the curve of blood concentration to the
duration of inducing period (six months). Tacrolimus ex-
posure = ∑n = 1
n (Cn * Tn)/∑n = 1
n (Tn), where n is the num-
ber of times of the blood concentration tested; Cn is the
tacrolimus blood concentration; Tn is the duration of
that blood concentration sustained for unchanged dos-
age of tacrolimus.
The CKD-EPI formula was used to estimate glomeru-
lar filtration rate (eGFR). Renal function decline was de-
fined as a >30%, > 40% or >50% decline of eGFR when
compared with baseline. A recovery of renal function de-
terioration was defined as the eGFR reverse to less than
15% decline compared with baseline.
Statistical analysis
Normally distributed variables are expressed as the mean
and standard deviation, and differences among groups
were analyzed by t test or one-way ANOVA analysis.
Qualitative data are described as percentages and analyzed
using Chi-square or Fisher’s exact test. Nonparametric
variables are expressed as median with interquartile range,
and compared using either Mann-Whitney or Kruskal-
Wallis test. Univariate followed by multiple logistic regres-
sion was used to determine associations between the
clinical factors and remission of nephrotic syndrome as
well. Only variables that with P value <0.1 in univariate lo-
gistic regression were further considered in the multiple
logistic regression models. The cumulative remission rates
of proteinuria were calculated using the Kaplan-Meier
method, in which patients with no remission of protein-
uria and discontinued tacrolimus treatment were consid-
ered as no remission lasting to the end of this study. The
P value reported was two sided and P < 0.05 was consid-
ered statistically significant. All analyses were performed
using R software (Version 3.1.2).
Results
Patients and baseline characteristics at the onset of
tacrolimus therapy
The screening profile of the current study is shown in
Fig. 1. Between 2004 and 2013, a total of 706 patients,
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who presented with IMN and were treated with tacroli-
mus during follow-up, underwent screening in this
study. Of these patients, 408 were enrolled in the study.
The following were reasons for exclusion: not meeting
the criteria for nephrotic syndrome (defined as serum al-
bumin < 30 g/L & proteinuria ≥3.5 g/24 h) at the onset
of tacrolimus therapy (227 patients), lost to follow-up
(30 patients), not following doctors’ orders (11 patients),
having no baseline data regarding 24 h urinary protein
or serum albumin (11 patients), combination treatment
with mycophenolate mofetil (7 patients), discontinued
tacrolimus treatment within two months due to substan-
tially low tacrolimus blood concentration (<1.0 ng/ml,
11 patients), coexisting kidney conditions at baseline (a
total of 3 patients: two patients with anti-GBM glomer-
ulonephritis and one with ANCA associated glomerulo-
nephritis), and combined with peritonitis that was not
associated with tacrolimus after three days of tacrolimus
treatment (one patient).
Of the 408 enrolled patients, 343 completed at least
six months of tacrolimus treatment and two patients
were less than six months and still under the treatment.
Sixty-three patients discontinued tacrolimus treatment
within six months. The main reasons for discontinuation
were adverse effects (47 patients, 75%) and premature
termination of tacrolimus for no remission of protein-
uria (15 patients, 23.8%); in addition, one patient discon-
tinued the tacrolimus treatment due to a diagnosis of a
hepatoma during treatment. In the 408 patients, the
tacrolimus treatment had been stopped by the time of
last follow up in 297 patients, while continued in 111
patients. The median follow up duration after tacrolimus
treatment start for patients included was 29.6 months
(interquartile range, 19.3–42.9 months) and the median
duration for tacrolimus treatment was 14.7 (8.3–23.3)
months. Among the 297 patients who stopped tacroli-
mus treatment during the follow-up, 63 (21%) of them
stopped within 6 months as described above, 59 (20%)
between 6 and 12 months, 126 (42.4%) between 12 and
24 months, and 49 (16.4%) after 24 months.
Baseline clinical characteristics of the 408 patients are
listed in Table 1. All patients showed nephrotic syndrome
at the onset of tacrolimus therapy. Fifteen patients (3.7%)
had an eGFR < 60 mL/min/1.73 m2 at baseline, but only
one patient had an eGFR <30 mL/min/1.73 m2. A total of
71 patients (17.4%) had received previous immunosup-
pressive treatments, including CNIs (Eleven patients: five
for tacrolimus and six for cyclosporine), corticosteroids,
cyclophosphamide, and mycophenolate mofetil. During
the tacrolimus treatment, 93.9% patients received con-
comitant treatment with steroid, and 69.4% patients with
angiotensin converting enzyme inhibitors and angiotensin
II receptor blockers (RASi).
Remission of proteinuria and factors associated with the
remission
Of the 408 patients enrolled, 271 (66.4%) achieved par-
tial or complete remission, and 95 (23.3%) achieved
Fig. 1 Study Enrollment. Of the 706 patients who were screened for participation in the study, 408 patients were enrolled in this study
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complete remission during the tacrolimus treatment. As
shown in Fig. 2, the cumulative remission rates of neph-
rotic syndrome (partial or complete remission) after the
beginning of the tacrolimus therapy, were as follows:
27% (95%CI, 22–31%), 50% (95%CI, 45–55%), 58%
(95%CI, 53–63%), 63% (95%CI, 58–67%), 65% (95%CI,
60–70%) and 67% (95%CI, 61–70%) at 3, 6, 9, 12, 18 and
24 months, respectively. The cumulative complete re-
mission rates after the beginning of tacrolimus therapy
were 0.7% (95%CI, 0–2%), 4% (95%CI, 2–6%), 9%
(95%CI, 6–12%), 13% (95%CI, 10–16%), 19% (95%CI,
15–22%) and 23% (95%CI, 19–27%) at 3, 6, 9, 12, 18 and
24 months, respectively. The median time to partial re-
mission was 3.7 (2.1–6.0) months, and that to complete
remission was 11.2 (8.0–17.4) months.
The clinical characteristics of patients with various re-
sponses to tacrolimus treatment (partial, complete and
no remission) are shown in Table 2. There was a lower
proportion of females and a shorter interval between ta-
crolimus treatment and the onset of renal disease, but a
higher proportion of previous immunosuppressive drugs
in the no remission group than the other two groups.
Age, proteinuria, and serum albumin at baseline were
similar among the three groups. The percentage of pa-
tients receiving corticosteroids or RASi concomitantly
with tacrolimus treatment did not differ among the three
groups of patients.
The induction period of tacrolimus treatment was de-
fined as the first 6 months of therapy. For each patient,
time average of blood tacrolimus exposure (tacrolimus
exposure) during the induction period was defined as
the ratio of the area under the curve of T0 blood con-
centration to the duration of the induction of the tacroli-
mus therapy (the first six months of tacrolimus therapy).
Compared with the other two groups, patients in the no
remission group had a significantly lower average tacro-
limus exposure.
Factors associated with remission of proteinuria were
further analyzed in logistic models (Table 3). In univariate
and multivariate logistic analyses, tacrolimus exposure,
gender, previous treatment with immunosuppressive ther-
apy and eGFR at baseline were significantly associated
with both partial remission and complete remission dur-
ing tacrolimus treatment, whereas age and proteinuria
were not. The multivariate logistic model showed that ta-
crolimus exposure (OR 1.2, 95% CI 1.1–1.3), gender (fe-
males vs male, OR 1.7, 95% CI 1.0–3.0), previous
immunosuppressive therapy (OR 0.39, 95% CI 0.22–0.67)
and eGFR at baseline (for every 10 mL/min/1.73 m2, OR
1.2, 95% CI 1.1–1.4) were independently associated with
partial remission after tacrolimus treatment. These four
factors were also independently associated with complete
remission after tacrolimus treatment.
Relapse of proteinuria and factors associated with the
relapse
The relapses were analyzed in 271 patients who achieved
partial or complete remission during the tacrolimus
treatment. A relapse occurred in 101 of those 271 pa-
tients, and 18 of whom relapsed after a complete remis-
sion of proteinuria. The median time to relapse after
partial remission or complete remission was 11.5 [6–18]
months, and after complete remission, it was 13 (9.2–
20.8) months. As shown in Fig. 3, the cumulative inci-
dences of relapse after partial remission or complete re-
mission was first achieved were 10% (95% CI, 6–13%),
Fig. 2 Cumulative remission rate of proteinuria during tacrolimus
treatment. Patients with no remission of proteinuria and
discontinued tacrolimus treatment were considered as no remission
lasting to the end of this study
Table 1 Characteristics of patients enrolled at baseline of
tacrolimus treatment
Items Total (N = 408)
Age 39 ± 16
Male gender (N, %) 298 (73%)
eGFR a at baseline 105 ± 25
eGFR < 60 15 (3.7%)
Proteinuria (g/24 h) 6.2 (4.7–8.0)
Serum albumin (g/L) 24.6 ± 3.4
Months since renal disease onset 6.6 (3.1–13.1)
Months since renal biopsy 4.6 (0.1–6.2)
Average tacrolimus doses during induction treatment 0.047 mg/kg
Average tacrolimus exposure (ng/ml) b 4.7 ± 2.1
Combined with RASi§ treatment 283 (69.4%)
Combined with corticosteroids 383 (93.9%)
Previous treatment with immunosuppressive drugs 71 (17.4%)
aeGFR, estimate glomerular filtration rate (mL/min/1.73 m2), calculated by CKD-
EPI formula; bSix patients were not monitored blood level of tacrolimus during
induction treatment; §RASi, angiotensin converting enzyme inhibitors and
angiotensin II receptor blockers
Qin et al. BMC Nephrology  (2017) 18:2 Page 4 of 9
21% (95% CI, 16–26%), 39% (95% CI, 32–45%) and 48%
(95% CI, 40–55%), respectively, at 6, 12, 24 and
36 months, whereas the cumulative incidences of relapse
after complete remission was first achieved were 1%
(95% CI, 0–3%), 11% (95% CI, 3–17%), 24% (95% CI,
12–35%) and 27% (95% CI, 14–39%), respectively, at 6,
12, 24 and 36 months.
It’s notable that 65.3% of relapse occurred before ta-
crolimus treatment stopped. At relapse, 36 patients had
stoped tacrolimus treatment, while 65 patients main-
tained at an average dosage of 2.3 mg/d. Among 101 pa-
tients who relapsed during follow-up, 34 patients didn’t
receive the steroid treatment at the time of relapse, while
67 patients remained the steroid treatment at an average
dosage of 11.3 mg/d (one patients 2.5 mg/d, forty-eight
patients between 5 mg-10 mg/d, and eighteen patients >
10 mg/d). We also analyzed factors associated with re-
lapse of proteinuria in 175 patients who achieved partial
remission after the treatment and discontinued tacrolimus
during follow up. In a multivariable COX analysis adjust-
ing for age, gender, baseline eGFR, the CR/PR status (HR
= 0.2, 95% CI 0.1–0.4, P < 0.001) and longer tapering dur-
ation (HR 0.97, 95%CI 0.94–0.99, P = 0.006) were inde-
pendent protective factors for the relapse. The longer
tapering duration, the lower risk of relapse.
Adverse events
A decline in eGFR was the most frequent adverse event
during tacrolimus treatment. A decline in eGFR may be
caused by nephrotoxicity of tacrolimus or progression of
nephrotic syndrome, which is difficult to differentiate in
clinical practice. However, once the decline in eGFR oc-
curred during tacrolimus treatment, nephrotoxicity of
tacrolimus should be considered for safety concerns.
The cumulative incidence of decline in eGFR is shown
in Fig. 4. The development of decline in eGFR is time








Age 40 ± 16 38 ± 16 37 ± 15 0.31
Gender (Female %) 21.2% 21.6% 45.3% <0.001
eGFR (mL/min/1.73 m2) 100 ± 28 107 ± 23 111 ± 22 0.008
eGFR < 60 mL/min/1.73 m2 6.6% 2.3% 2.1% 0.11
Proteinuria, g/24 h 6.4 (4.7–8.4) 6.1(4.8–7.9) 5.9 (4.7–7.4) 0.37
Serum albumin (g/L) 24.2 ± 3.4 24.7 ± 3.3 24.8 ± 3.4 0.30
Previous treatment with immunosuppressive drugs 26.3% 14.7 9.5% 0.002
Combined with RASi treatment 68.6% 71.5% 66.3% 0.65
Combined with corticosteroids 90.5% 94.9% 96.8% 0.11
Tacrolimus treatment since onset of disease (months) 7.6 (3.9–14.8) 7.3 (2.9–13.3) 5.1 (2.1–9.5) 0.001
Tacrolimus exposure (ng/mL) 4.2 ± 2.0 4.7 ± 2.1 5.2 ± 2.2 0.002
Table 3 Factors predicting remission of nephrotic syndrome after tacrolimus treatment in univariate and multivariate logistic model
Variables Partial or complete remission Complete remission
OR 95% CI P-Value OR 95% CI P-Value
Univariate logistic models
Gender (Female vs. Male) 1.6 0.99–2.6 0.06 3.1 1.9–4.9 <0.001
eGFR at baseline (for every 10 mL/min/1.73 m2) 1.1 1.0–1.2 0.003 1.1 1.0–1.2 0.06
Proteinuria at the onset of tacrolimus therapy 0.94 0.87–1.0 0.11 0.94 0.86–1.0 0.22
Previous treated with immunosuppressive drugs
(Yes vs. No)
0.42 0.25–0.70 <0.001 0.42 0.19–0.85 0.02
Average tacrolimus exposure (ng/mL) 1.2 1.1–1.3 0.004 1.2 1.0–1.3 0.005
Multivariate logistic model
Gender (Female vs. Male) 1.7 1.0–3.0 0.04 3.3 2.0–5.6 <0.001
Previous treatment with immunosuppressive drugs
(Yes vs. No)
0.39 0.22–0.67 <0.001 0.40 0.17–0.83 0.02
eGFR at baseline (for every 10 mL/min/1.73 m2) 1.2 1.1–1.4 0.001 1.1 0.99–1.2 0.07
Average tacrolimus exposure (ng/mL) 1.2 1.1–1.3 0.001 1.2 1.0–1.2 <0.001
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dependent, and it can occur at any time during tacroli-
mus treatment. The cumulative incidences of a ≥30% de-
crease in eGFR during tacrolimus treatment were 9%
(95% CI, 7% to 13%), 16% (95% CI, 12% to 20%) and
28% (95% CI, 22% to 33%) at 6, 12 and 24 months, re-
spectively; the cumulative incidences of a ≥40% decrease
in eGFR were 6% (95% CI, 3% to 7%), 10% (95% CI, 7%
to 13%) and 15% (95%CI, 10% to 20%) at 6, 12 and
24 months, respectively. The cumulative incidences of a
≥50% decrease in eGFR were 2% (95% CI, 0% to 3%), 3%
(95% CI, 1% to 5%) and 6% (95% CI, 2% to 10%) at 6, 12
and 24 months, respectively.
Of the 83 patients with ≥ 30% decline of eGFR, the ta-
crolimus was discontinued in 57% patients, reduced in
30% patients and sustained in 13% patients. CR/PR sta-
tus was achieved before eGFR event occurred in 37 pa-
tients, seventeen (45.9%) of these patients had eGFR
recovered in the follow up. Forty-six patients had sus-
tained proteinuria when eGFR event occurred, nine
(19.6%) of them had eGFR recovered in the follow up
(Fig. 5a). Of the 43 patients with a ≥ 40% decrease in
eGFR. Tacrolimus treatment was discontinued or ta-
pered in 40 (93%) patients. Fourteen of these patients
showed a partial or complete remission of nephrotic
syndrome before the eGFR event occurred, in which 4
patients (28.6%) had their eGFR recovered in the follow
up. Twenty-nine patients had sustained proteinuria and
six of these patients (20.7%) had eGFR level recovered
(Fig. 5b). Of the 14 patients with a ≥ 50% decrease in
eGFR, tacrolimus treatment were all discontinued or ta-
pered. There were 5 patients achieved partial or
complete remission of nephrotic syndrome before eGFR
event and none of them had eGFR recovered in the fol-
low up. Nine patients had no remission of nephrotic
syndrome and only one of them had eGFR level recov-
ered (11.1%) (Fig. 5c).
Other notable adverse reactions are shown in Table 4.
Infections occurred in 36 cases (8.8%, 14 cases were
treated in the hospital), newly developed hyperglycemia
occurred in 28 cases (6.9%), neurological adverse reactions
developed in 31 cases (7.6%) and cardiovascular adverse
reactions (Six patients had tachycardia; one patient had
bradycardia; one patient had tachycardia and angina; one
patients had angina) occurred in 9 patients (2.2%).
Discussion
Our study shows that a remission of nephrotic syndrome
was observed in 66% of the examined Chinese patients
with IMN during tacrolimus treatment. The cumulative
remission rates (partial or complete remission) was 50%
and 63% within 6 and 12 months, respectively, after the
onset of tacrolimus therapy in the current study (Fig. 2).
The remission rate of tacrolimus therapy in this study is
slightly lower than that in previous studies [7–9, 15]. A
Fig. 3 The cumulative incidences of relapse after partial remissions (3a) and complete remissions (3b)
Fig. 4 The incidences of decrease of eGFR during the treatment
of tacrolimus
Qin et al. BMC Nephrology  (2017) 18:2 Page 6 of 9
small RCT showed that the remission rate of proteinuria
was 72% (18/25) after 12 months of tacrolimus mono-
therapy compared with 22% (5/23) in the supportive
therapy group [9]. Another small RCT from China
showed that the remission rate (partial or complete re-
mission) was significantly higher in the tacrolimus group
(85%, 33/39) than in the CTX group after 6 months of
treatment (65%, 22/34) [8]. Recently, a study in India
had observed remission rate of 71% at 12 month with ta-
crolimus treatment [15]. The lower remission rate ob-
served in the current study than in previous studies can
be explained by the finding that the tacrolimus blood
levels in this study were relatively lower than those in
previous studies [8, 16]. It’s notable that the tacrolimus
treatment was continued in 111 patients at the end of
follow up, the remission rate may go higher if we keep
Fig. 5 Follow up of patients with ≥30 (a), 40 (b) or 50% (c) eGFR decrease. A recovery of renal function deterioration was defined as the eGFR
reverse to less than 15% decline compared with baseline
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following up of these patients. Furthermore, tacrolimus
treatment was discontinued in 63 patients for various rea-
sons within six months of the treatment, and most of those
patients were considered to have no remission during the
tacrolimus treatment. If those patients who discontinued
tacrolimus treatment before remission were considered
censored observations, the Kaplan–Meier method would
dramatically over estimate the remission rate.
Tacrolimus exhibit highly individual variations in
pharmacokinetics and pharmacodynamics Therefore,
therapeutic drug monitoring of tacrolimus is universally
applied in solid organ transplantation and treatment of
glomerular disease. We found that tacrolimus exposure
during the treatment induction period is independently
predictive of the probability of remission in this study: the
higher the tacrolimus exposure, the higher the probability
of remission. However, under higher exposure, risk of side
effect, especially nephrotoxicity also went higher, which
made the decision of tacrolimus doses difficult.
One of the most concern of tacrolimus treatment was
its nephrotoxicity. In this study, renal function decline
(defined by >40% decline in eGFR) was seen in a total of
43 patients (10.5%). Previous Studies showed that renal
function decline was largely observed in patients re-
ceived tacrolimus for immunosuppression after kidney
or non-kidney transplantation and other autoimmune
disease [17–21]. Higher tacrolimus exposure, though
resulted in a higher remission rate, may at the same time
increase the incidence of renal function decline. Tacroli-
mus related nephrotoxicity is associated with both irrevers-
ible or reversible histologic damage to all compartments of
the kidneys, including the glomeruli, arterioles, and
tubulo-interstitium, but the non-specificity of most lesions
makes the differential diagnosis regarding other injurious
processes cumbersome [19]. However, it’s worth to men-
tion that in some patients the renal function decline might
be attributed to the development of IMN but not tacroli-
mus. In clinical practice, we could hardly differentiate ta-
crolimus related nephrotoxicity or renal damage from
sustained proteinuria related renal function decline. We
also lacked a biomarker that could specifically predict ta-
crolimus related nephrotoxicity. In our study, there were
four patients who achieved CR/PR before ≥40% eGFR de-
cline occurred and had their eGFR level recovered after ta-
crolimus treatment tapered or withdrawal. The renal
function decline in these four patients should be attributed
to tacrolimus related nephrotoxity. There were also nine
patients who achieved CR/PR and with irreversible eGFR
decline after treatment withdrawal. In these patients, tacro-
limus related nephrotoxicity should also be carefully con-
sidered. It’s worth to mention that in patients with a
remission but renal function decline > 50%, none had their
eGFR recovered, indicating that tacrolimus might have re-
sulted in an irreversible renal function damage in these pa-
tients. Taken together, our data indicated that tacrolimus
treatment might related to considerable renal function
decline while lack specific biomarker for identifying
nephrotoxity.
In addition to tacrolimus exposure, female gender, no
history of previous immunosuppressive therapy and a
higher eGFR at baseline were independently associated
with a higher probability of remission during tacrolimus
therapy. The associations between these three factors
and remission were also observed in a recent study [16].
However, the amount of proteinuria at baseline was not
significantly associated with the probability of remission.
A high rate of relapse was also observed in this study.
Patients with partial remission were followed by a higher
likelihood of relapse than those with complete remission.
A previous study suggested that the relapses may be
partly prevented by a longer tapering period [16]. In the
current study, we also found the longer tapering dur-
ation, the less chance of relapse. However, longer tacroli-
mus treatment could also associated with an increased
incidence of nephrotoxicity. The optimal tapering strat-
egy remains to be determined.
There exist some limitations in the current study. Due
to its retrospective nature, it was rather hard to control
the time duration of tacrolimus treatment, which may in-
fluence the efficacy observed. It’s also important to realize
that in fact IMN patients can achieve spontaneous
remission rate under only supportive treatment (ACEIs or
ARBs) [15, 22], so the remission rate observed in the
current study might over estimate tacrolimus efficacy to
some extent. To precisely describe the efficacy of
Table 4 Other adverse events associated with tacrolimus
treatment
Adverse events Number of patients















Cardiovascular system 9 (2.2%)
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tacrolimus, a well-controlled clinical trial shall be carried
out in the future.
Conclusion
Low dose tacrolimus is effective for IMN. Renal function
decline was not rare in patients treated with tacrolimus.
Besides the safety concerns, a rather high relapse rate
was also of great consideration in tacrolimus treatment.
Our findings validates the effectiveness of tacrolimus in
a large number of IMN patients, however, large RCT
studies still seems to be necessary before more extensive
use of tacrolimus.
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